ARG1 and neoplasm: Orillion et al. reported that entinostat reduced the expression of ARG1, iNOS, and COX2 by MDSCs, and that the combination of entinostat plus anti-PD-1 antibodies increased survival and delayed tumor growth significantly in several preclinical mouse models [96].